Consultants in Neurology, Ltd. | Northbrook, IL

Research site

(Unclaimed)

Location

1535 Lake Cook Road, Suite 601, Northbrook, Illinois, United States of America

Site insights

Top conditions

Top treatments

Tolebrutinib

SAR442168

Ocrelizumab

AVP-923

Tyrosine

Fampridine

Satralizumab

Ozanimod

Copaxone

Frexalimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 43 total trials

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis.

Active, not recruiting

Relapsing Remitting Multiple Sclerosis

Other: placebo

Drug: orelabrutinib

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting

Multiple Sclerosis

Drug: Ocrelizumab

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and...

Enrolling

Multiple Sclerosis

Drug: LY3541860

Drug: Placebo

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)

The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occur...

Enrolling

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Other: Placebo

Drug: Satralizumab

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (FREXALT)

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling

Multiple Sclerosis

Drug: Activated charcoal

Drug: Cholestyramine

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling

Multiple Sclerosis

Drug: Frexalimab

Drug: Placebo

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have particip...

Enrolling

Relapsing Multiple Sclerosis

Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)

Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMSSecondary Objective:To evalu...

Active, not recruiting

Secondary Progressive Multiple Sclerosis

Drug: Placebo to match Tolebrutinib

Drug: Tolebrutinib

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple scler...

Enrolling

Primary Progressive Multiple Sclerosis

Drug: Tolebrutinib

Drug: Placebo

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Primary Objective:To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated...

Active, not recruiting

Relapsing Multiple Sclerosis

Drug: Placebo to match Teriflunomide

Drug: Placebo to match Tolebrutinib

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

Primary Objective:To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated...

Active, not recruiting

Relapsing Multiple Sclerosis

Drug: Placebo to match Teriflunomide

Drug: Tolebrutinib

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (CALLIPER)

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressiv...

Active, not recruiting

Multiple Sclerosis

Drug: Placebo matching IMU-838

Drug: IMU-838

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-1)

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Re...

Enrolling

Multiple Sclerosis

Drug: IMU-838 tablets

Drug: Placebo matching IMU-838 tablets